Lipidavit Sl (Phospholipids From Soya Beans)

The phospholipids are amphiphilic molecules that position themselves at oil‑water interfaces, lowering surface tension. This creates stable micelles or liposomes that encapsulate lipophilic drugs, enhancing their solubility and ensuring uniform distribution within the final pharmaceutical product.

The amount of Lipidavit Sl required is determined by the formulation scientist or prescriber based on the specific drug product being developed. Dosing is not standardized and should be set according to the manufacturing specifications of each pharmaceutical preparation.

Safety data for phospholipids from soya beans as an excipient in pregnancy or lactation are limited. Manufacturers typically assess risk on a case‑by‑case basis, and the prescriber should evaluate the benefit‑risk profile before inclusion in products intended for pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lipidavit Sl offers a soy‑derived phospholipid profile that is comparable to other soy‑based excipients but is distinguished by its EU‑origin quality standards and consistent emulsifying performance. Choice of excipient often depends on regulatory preferences, source material, and specific formulation requirements.

Store Lipidavit Sl at temperatures below 25 °C in its original packaging. Protect it from moisture, direct sunlight, and extreme temperature fluctuations to maintain its functional integrity as an emulsifier and solubilising agent.

Lipidavit Sl is incorporated into the manufacturing process of oral or parenteral drug products. It is not administered directly to patients; instead, it becomes part of the final dosage form, such as tablets, capsules, or injectable solutions, where it performs its excipient functions.

The most serious risks involve hypersensitivity reactions, including anaphylaxis, angioedema, and severe urticaria, particularly in individuals with known soy allergy. Immediate medical attention is required if any signs of a severe allergic response occur.

Patients with a documented allergy to soy or soy‑derived phospholipids should avoid products containing Lipidavit Sl. Additionally, individuals with severe hepatic impairment should use such formulations only under medical supervision.